BLUE Brings Back Treatment From Marketing Suspension

The stock experienced a steep bear gap related to this suspension in February

Deputy Editor
Jul 9, 2021 at 10:36 AM
facebook twitter linkedin

The shares of bluebird bio Inc (NASDAQ:BLUE) are higher today, on news that the biotech company is lifting its voluntary marketing suspension of its gene therapy treatment, Zynteglo. The drug, which treats a rare blood condition, received a positive recommendation from a European regulator, which says its benefit-risk balance remains favorable. BLUE is up 1.5% to trade at $30.90 at last check. 

The stock has struggled to climb back up the charts after its steep mid-February bear gap, which occurred after the company placed its sickle cell disease treatment LentiGlobin on temporary suspension following a serious adverse reaction, and suspended Zynteglo as it is made with the same component. However, the stock appears to have found a floor at the $30 level, though long-term pressure at the 120-day moving average still looms. Year-to-date, the equity is down 28.6%. 

Analysts are mostly hesitant toward BLUE, with 11 of the 14 in coverage carrying a "hold" rating, with three at a "strong buy." Meanwhile, short interest makes up 8.1% of the stock's available float, or over four days' worth of pent-up buying power. 

The options pits, on the other hand, have been overwhelmingly bullish. This is per bluebird stock's 50-day call/put volume ratio of 22.67 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 92% of readings from the past year. 

It's also worth pointing out that BLUE ranks low on the Schaeffer's Volatility Scorecard (SVS), with a score of just 9 out of 100. In other words, the security has consistently realized lower volatility than its options have priced in, making the stock a potential premium-selling candidate.



Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners